Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma result in significantly elevated expression of ferroptosis-protective genes, such as AKR1C1/2/3, and resistance to pharmacologically induced ferroptosis [41]. This evidence concerns the gene AKR1C1 and lung adenocarcinoma.